Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)(TERMINATED) - Full Text View

Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)(TERMINATED)

This study has been terminated.

Sponsored by:	Schering-Plough
Information provided by:	Schering-Plough
ClinicalTrials.gov Identifier:	NCT00034684

Purpose

The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, or Acute Lymphoblastic Leukemia.

Condition	Intervention	Phase
Leukemia Myelodysplastic Syndromes Leukemia, Myeloid, Chronic Blast Crisis Leukemia, Lymphocytic	Drug: Farnesyl Protein Transferase Inhibitor	Phase I Phase II

MedlinePlus related topics:

Leukemia, Adult Acute Leukemia, Adult Chronic

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety Study

Official Title:	Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia

Further study details as provided by Schering-Plough:

Estimated Enrollment:	90
Study Start Date:	June 2001
Estimated Study Completion Date:	March 2004

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Pathologically documented chronic myelogenous leukemia in blast crisis, myelodysplasia, acute myelogenous leukemia, or acute lymphocytic leukemia.
Life expectancy of 12 weeks or greater.
ECOG Performance Status less than or equal to 2.
Meets protocol requirements for specified laboratory values.
No manifestations of a malabsorption syndrome.

Exclusion Criteria:

Patients who have received more than three chemotherapy regimens for more than three recurrences of the disease.
Poor medical risks because of nonmalignant systemic disease as well as those with active uncontrolled conditions.
Patients who have received investigational therapy of any type within 30 days prior to administration.

Contacts and Locations

No Contacts or Locations Provided

More Information

Study ID Numbers:	P00701
First Received:	May 1, 2002
Last Updated:	May 31, 2006
ClinicalTrials.gov Identifier:	NCT00034684
Health Authority:	United States: Food and Drug Administration

Keywords provided by Schering-Plough:

Leukemia

Myelodysplastic Syndromes

Leukemia, Myeloid

Leukemia, Lymphocytic

Study placed in the following topic categories:

Myelodysplastic syndromes

Blast Crisis

Leukemia, Lymphoid

Immunoproliferative Disorders

Precancerous Conditions

Hematologic Diseases

Myelodysplasia

Myelodysplastic Syndromes

Myeloproliferative Disorders

Leukemia, Myeloid

Leukemia

Lymphatic Diseases

Preleukemia

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Bone Marrow Diseases

Lymphoproliferative Disorders

Additional relevant MeSH terms:

Neoplastic Processes

Neoplasms

Disease

Pathologic Processes

Neoplasms by Histologic Type

Immune System Diseases

Syndrome

Cell Transformation, Neoplastic

ClinicalTrials.gov processed this record on November 30, 2008